Drug Trial Radar · NCT07116915
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Aug 11, 2025
Primary completion
Aug 14, 2026
Study completion Aug 14, 2026
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD
Conditions
- COPD
Interventions
HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspensionDrug
HRS-9821 Powder for Inhalation. HRS-9821 inhalation suspension
HRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placeboDrug
HRS-9821 Powder for Inhalation placebo. HRS-9821 inhalation suspension placebo
Moxifloxacin Hydrochloride TabletsDrug
Moxifloxacin Hydrochloride Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the rate of adverse eventsTime frame: The screening period lasted until 40 days after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.